Jefferies Financial Group Inc. acquired a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the third quarter, HoldingsChannel reports. The institutional investor acquired 4,275 shares of the biotechnology company’s stock, valued at approximately $1,335,000.
Several other hedge funds have also added to or reduced their stakes in LGND. Janus Henderson Group PLC boosted its stake in Ligand Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 1,009,891 shares of the biotechnology company’s stock worth $201,623,000 after purchasing an additional 14,491 shares in the last quarter. Ranger Investment Management L.P. purchased a new stake in Ligand Pharmaceuticals during the 2nd quarter valued at about $81,424,000. Rice Hall James & Associates LLC increased its stake in Ligand Pharmaceuticals by 1.4% during the 1st quarter. Rice Hall James & Associates LLC now owns 283,567 shares of the biotechnology company’s stock valued at $56,614,000 after purchasing an additional 3,940 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Ligand Pharmaceuticals during the 2nd quarter valued at about $41,429,000. Finally, Bank of America Corp DE increased its stake in Ligand Pharmaceuticals by 31.4% during the 1st quarter. Bank of America Corp DE now owns 157,865 shares of the biotechnology company’s stock valued at $31,518,000 after purchasing an additional 37,696 shares in the last quarter. 91.28% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $313.22, for a total transaction of $1,566,100.00. Following the completion of the sale, the insider directly owned 31,854 shares in the company, valued at approximately $9,977,309.88. The trade was a 13.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Aryeh sold 3,000 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total value of $960,150.00. Following the transaction, the director directly owned 105,476 shares in the company, valued at $33,757,593.80. The trade was a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 21,593 shares of company stock valued at $6,585,447. Company insiders own 5.60% of the company’s stock.
Ligand Pharmaceuticals Stock Performance
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $2.67 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The firm had revenue of $78.75 million during the quarter, compared to analyst estimates of $77.00 million. During the same period in the previous year, the business posted $3.09 earnings per share. The business’s revenue for the quarter was down 31.8% on a year-over-year basis. On average, research analysts expect that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Royal Bank Of Canada upped their target price on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Leerink Partners started coverage on Ligand Pharmaceuticals in a research report on Friday, August 14th. They issued an “outperform” rating and a $330.00 price objective on the stock. Weiss Ratings downgraded Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research note on Monday, November 2nd. Citigroup increased their target price on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $358.00 target price on shares of Ligand Pharmaceuticals in a report on Thursday, September 24th. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $355.38.
Check Out Our Latest Research Report on Ligand Pharmaceuticals
Ligand Pharmaceuticals Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Read More
- Five stocks we like better than Ligand Pharmaceuticals
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report).
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
